APA

Kubesova B., Pavlova S., Malcikova J., Kabathova J., Radova L., Tom N., Tichy B., Plevova K., Kantorova B., Fiedorova K., Slavikova M., Bystry V., Kissova J., Gisslinger B., Gisslinger H., Penka M., Mayer J., Kralovics R., Pospisilova S. & Doubek M. (20190102). Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. : Leukemia.

Chicago

Kubesova B, Pavlova S, Malcikova J, Kabathova J, Radova L, Tom N, Tichy B, Plevova K, Kantorova B, Fiedorova K, Slavikova M, Bystry V, Kissova J, Gisslinger B, Gisslinger H, Penka M, Mayer J, Kralovics R, Pospisilova S and Doubek M. 20190102. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. : Leukemia.

Harvard

Kubesova B., Pavlova S., Malcikova J., Kabathova J., Radova L., Tom N., Tichy B., Plevova K., Kantorova B., Fiedorova K., Slavikova M., Bystry V., Kissova J., Gisslinger B., Gisslinger H., Penka M., Mayer J., Kralovics R., Pospisilova S. and Doubek M. (20190102). Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. : Leukemia.

MLA

Kubesova B, Pavlova S, Malcikova J, Kabathova J, Radova L, Tom N, Tichy B, Plevova K, Kantorova B, Fiedorova K, Slavikova M, Bystry V, Kissova J, Gisslinger B, Gisslinger H, Penka M, Mayer J, Kralovics R, Pospisilova S and Doubek M. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. : Leukemia. 20190102.